A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM

Stopped Business decision to move away from this indication with this intervention, and low enrollment.

Conditions

• Diabetes Mellitus, Type 2
• Obesity

Interventions

• DRUG: HT-6184
• DRUG: HT-6184 Matching Placebo
• DRUG: Semaglutide 1 mg

Sponsor

Halia Therapeutics, Inc.